Feed NLSP
NL

NLS Pharmaceutics AG

NLSP · NASDAQ

$3.15 -4.83% (-$0.16)
Piotroski F-Score Weak
2/9
Valuation
-
N/A
EV/FFO N/A
P/S N/A
P/B N/A
Growth
-
N/A
Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A
ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A
Current ratio N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
0 /100
Unstable
Beta 0.13x
EPS volatility N/A
Profitable years N/A

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre NLSP
Online

Despre companie

NLS Pharmaceutics AG (NLS) is a Swiss biotechnology company focused on the development of innovative drugs for the treatment of neurological and psychiatric disorders. With a primary focus on researching and developing medications for epilepsy and mood disorders, NLS Pharmaceutics aims to address unmet needs in the treatment of these diseases. The company is known for its expertise in pharmacology and neuroscience and for its commitment to innovation and discovering new therapeutic approaches. Shares of NLS Pharmaceutics AG (NLS) could be suitable for investors looking to invest in the biotechnology sector with an emphasis on treating neurological and psychiatric disorders.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Alexander Zwyer

Employees

6

Headquarters

Zurich

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.